🔎 Trials Near Me

Home › Acute Biphenotypic Leukemia › Massachusetts

Pag-aaral pangklinika para sa Acute Biphenotypic Leukemia sa Massachusetts

5 pag-aaral para sa Acute Biphenotypic Leukemia ang naghahanap ng mga kalahok sa mga site sa Massachusetts.

Mga Lungsod sa Massachusetts

Opisyal na teksto ng pag-aaral (English)

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Dana-Farber Cancer Institute, Boston
  • UMass Memorial Medical Center - University Campus, Worcester
Nagre-recruitPhase 2
365 Days · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06317662

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Massachusetts General Hospital Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
  • Baystate Medical Center, Springfield
  • at 1 pa
Nagre-recruitPhase 3
365 Days – 25 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1/2
Hanggang edad 22 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04726241

Venetoclax Basket Trial for High Risk Hematologic Malignancies

  • Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1
Edad 1 hanggang 40 · Lahat ng kasarian · Na-update Mar 12, 2026 · NCT05292664

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1
Edad 1 hanggang 21 · Lahat ng kasarian · Na-update Dis 6, 2024 · NCT05476770

Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.